Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

GRAL vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–6 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: GRAL 1 – 5 TWST Matrix Metrics: GRAL 6 – 4 TWST

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin).

  • Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. TWST 51.7/100 HOLD), TWST captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-28.8% vs. -332.0% operating margin) and revenue trajectory (+27.9% vs. +3.7% YoY).
  • Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GRAL vs TWST
GRAL NASDAQ
GRAIL, Inc. Common Stock
Services-Medical Laboratories
$105.60
-8.88% 1D
Market Cap $5.2B
TTM Revenue $167M
Forward P/E 1.1x
Beta / 30D Vol 3.09β · 99% Vol
Unified Composite Score
54.5 / 100 HOLD
Tech 35.0 Fund 49.0 Flow 57.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 37.7 · SMA20: $132.32 · SMA50: $121.37
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.04
-5.88% 1D
Market Cap $7.4B
TTM Revenue $459M
Forward P/E N/M
Beta / 30D Vol 3.13β · 126% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.8 · SMA20: $137.31 · SMA50: $149.83

6-Pillar Scorecard Institutional Category Breakdown (GRAL 1 – 5 TWST)

Columns: Metric · GRAL · TWST
1. Valuation Multiples GRAL
Forward P/E 1.1x N/M
Trailing P/E 1.1x N/M
PEG Ratio N/M N/M
EV / Revenue 31.6x 16.1x
2. Growth & Scale TWST
Revenue Growth (YoY) +3.7% +27.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $167M $459M
Market Cap $5.2B $7.4B
3. Profitability & Quality TWST
Gross Margin 46.7% 52.4%
Operating Margin -332.0% -28.8%
Net Profit Margin -243.8% -28.3%
Return on Equity (ROE) -17.3% -19.1%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) -$312M -$107M EBITDA
Cash Flow Margin N/A -23.4% EBITDA Mgn
Net Cash / Leverage $57M Net Debt (0.03x D/E) $13.61 Book/Sh · -19.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 93.0% (53rd %ile) 100.1% (19th %ile)
Put/Call OI Skew 0.81x (Call-Skewed) 1.04x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity N/A 81.2% of Rev ($373M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GRAL (6) vs TWST (4)
Institutional Metric GRAL TWST Criterion Row Edge
Market Capitalization
Scale
$5.2B $7.4B Larger Scale TWST
Trailing P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Forward P/E Ratio
Valuation
1.1x N/M Lower Multiple GRAL
Revenue Growth (YoY)
Growth
+3.7% +27.9% Higher Growth TWST
Operating Margin (TTM)
Profitability
-332.0% -28.8% Higher Margin TWST
Net Profit Margin
Profitability
-243.8% -28.3% Higher Margin TWST
Return on Equity (ROE)
Capital Efficiency
-17.3% -19.1% Higher ROE GRAL
52-Week Range Position
Momentum
51% ($42–$166) 42% ($23–$220) Stronger Trend GRAL
Beta / 30D Volatility
Risk Regime
3.09β · 99% Vol 3.13β · 126% Vol Lower Realized Risk GRAL
Unified Institutional Score
Composite Signal
54.5 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite GRAL
Trailing 12M Revenue (USD)
Operating Scale
$167M $459M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
46.7% 52.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 31.6x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$312M ($57M Net Debt (0.03x D/E)) -$107M EBITDA ($13.61 Book/Sh · -19.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRAL +10.51 pp
GRAL: -10.36% · TWST: -20.87%
3M Horizon GRAL +66.53 pp
GRAL: +50.96% · TWST: -15.57%
6M Horizon TWST +36.6 pp
GRAL: +77.03% · TWST: +113.63%
1Y Horizon TWST +224.38 pp
GRAL: +26.92% · TWST: +251.3%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period GRAL Revenue TWST Revenue GRAL Op. Margin TWST Op. Margin Margin Leader
FY2018 N/A $30M N/A -277.5% TWST
FY2019 N/A $50M N/A -200.1% TWST
FY2020 N/A $90M N/A -155.5% TWST
FY2021 N/A $130M N/A -115.4% TWST
FY2022 N/A $200M N/A -115.3% TWST
FY2023 $90M $250M -1627.6% -88.6% TWST
FY2024 $130M $310M -1743.0% -70.6% TWST
FY2025 $150M $380M -382.0% -36.2% TWST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GRAL BREAKDOWN
12d in phase · OBV DISTRIBUTION
Current IV 93.0%
IV Percentile 53rd %ile
Put/Call OI Skew 0.81x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact GRAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 100.1%
IV Percentile 19th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GRAL Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $5.2B market capitalization and -332.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.4B market capitalization and -28.8% operating margin.
OpEx & R&D Reinvestment 81.2% of Rev ($373M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ GRAL vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over GRAIL, Inc. (GRAL) in the Tradestie Institutional Equity Comparison Engine, winning 4–6 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRAL carries a Unified Composite Score of 54.5/100 (HOLD) at $105.60 (1.1x Forward P/E, -332.0% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.04 (N/M Forward P/E, -28.8% operating margin). Composite vs. Pillar Nuance: While GRAL currently prints a higher short-term Unified Composite Score (54.5/100 HOLD vs. TWST 51.7/100 HOLD), TWST captures the overall institutional head-to-head verdict (4–6 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-28.8% vs. -332.0% operating margin) and revenue trajectory (+27.9% vs. +3.7% YoY). Technical & Structure Timing Caution: GRAL is currently in a Breakdown options structure phase (RSI 37.7); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: GRAL posts +3.7% YoY revenue growth and +0.0% YoY earnings growth on $167M TTM revenue (46.7% gross margin, -332.0% operating margin), compared with TWST at +27.9% YoY revenue growth and +0.0% YoY earnings growth on $459M TTM revenue (52.4% gross margin, -28.8% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), GRAL cumulative revenue shifted +66.7% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, GRAL deploys N/A (0 90-day corporate R&D disclosures) versus 81.2% of Rev ($373M) (0 disclosures) for TWST.

GRAL screens cheaper on headline valuation multiples. GRAL trades at 1.1x Forward P/E, 1.1x Trailing P/E, N/M PEG, and 31.6x EV/Revenue (unreported FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.1x EV/Revenue (-23.4% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRAL (-17.3% ROE) versus TWST (-19.1% ROE) capital efficiency.

In options market volatility and institutional positioning, GRAL carries 93.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), a 0.81x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.09β · 99% Vol realized risk). By comparison, TWST carries 100.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.13β · 126% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.